A phase 2B randomised trial of hyperbaric oxygen therapy for ulcerative colitis patients hospitalised for moderate to severe flares.

Parambir S DulaiLaura E RaffalsDavid HudesmanMichael ChioreanRaymond CrossTasneem AhmedMichael WinterShannon ChangDavid FudmanCharlotte SadlerErnest L ChiuFrank L RossGary ToupsM Hassan MuradKinjal SethuramanJames R HolmRenie GuilliodBenjamin LevineJay C BuckeyCorey A Siegel

Published in: Alimentary pharmacology & therapeutics (2020)

Hyperbaric oxygen appears to be effective for optimising response to intravenous steroids in UC patients hospitalised for acute flares, with low rates of re-hospitalisation or colectomy at 3 months. An optimal clinical response is achieved with 5 days of hyperbaric oxygen. Larger phase 3 trials are needed to confirm efficacy and obtain labelled approval.

Keyphrases

end stage renal disease
newly diagnosed
ejection fraction
prognostic factors
ulcerative colitis
clinical trial
randomized controlled trial
liver failure
early onset
study protocol
high intensity